Integrated pharmaceutical care service model using personalized mobile applications for patients with rheumatoid arthritis

Daegu Catholic University Medical Center0 个研究点目标入组 282 人开始时间: 待定最近更新: 2021年8月30日

试验速览

暂无简介。

•1) Among outpatients 18 years of age or older who visit the Department of Rheumatology at Daegu Catholic University Hospital, those who have been diagnosed with rheumatoid arthritis and have received one or more of the following DMARDs
•- Conventional DMARDs: Hydroxychloroquine, methotrexate, sulfasalazine, bucillamine, leflunomide, tacrolimus
•- Biologic DMARDs (subcutaneous): etanercept, adalimumab, golimumab, tocilizumab, abatacept
•- JAK inhibitor: tofacitinib, baricitinb, upadacitinib
•2) Patients who started taking a new drug (DMARD, steroid, or analgesic) at the time of randomization
•3) Persons with mobile devices (smartphones, etc.)
•4) Patients who agreed to participate in the study

•1) Patients who have difficulty responding to written or interview questionnaires due to cognitive impairment, etc.
•2) Patients with severe systemic or malignant disease
•3) Patients who do not agree to install the medication guide tool (an application or app developed in this study) on the mobile device
•4) Patients who do not agree to provide medication information using Multimedia Messaging Service (MMS)
•5) Patients judged by other researchers as inappropriate to participate in the study

发起方

Daegu Catholic University Medical Center